doi: 10.1016/0024-3205(92)90504-i
Scott RA, Lagou V, Welch RP, Wheeler E, Montasser ME, Luan J, Mgi R, Strawbridge RJ, Rehnberg E, Gustafsson S, Kanoni S, Rasmussen-Torvik LJ, Yengo L, Lecoeur C, Shungin D, Sanna S, Sidore C, Johnson PCD, Jukema JW, Johnson T, Mahajan A, Verweij N, Thorleifsson G, Hottenga J-J, Shah S, Smith AV, Sennblad B, Gieger C, Salo P, Perola M, et al
You're experiencing any kind of infection
This phase II trial demonstrates that enobosarm, a selective AR modulator, shows anti-tumour activity and clinical benefit in women in postmenopause with ER-positive, HER2-negative and AR-positive advanced breast cancer, supporting further investigation of AR activation as a therapeutic strategy
Accordingly, we observed more male patients and fewer asymptomatic male carriers, whereas among females, this pattern was reversed, with more asymptomatic carriers than patients